English | Español

Regulatory
+ Regulatory
A. L. Albert | Jul 8, 2026

Public Policy Solutions: 'Americans deserve transparency into programs like 340B'
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Study finds socioeconomic status affects metabolic disease rates differently across racial groups
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Illinois emergency departments face challenges in pediatric mental health crisis care
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Biopharma sees selective recovery as major VC rounds mark H1 2026
+ Regulatory
Patient Daily | Jul 8, 2026

American Association of Nurse Practitioners announces 2026 grants and scholarships recipients
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Local youth leaders honored for tobacco-free advocacy at statewide summit
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Xaira Therapeutics seeks partners to expand data for AI-driven drug discovery
+ Pharmaceuticals
Patient Daily | Jul 8, 2026

Antihistamines and colchicine show modest short-term benefit for long Covid fatigue, study finds

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation